Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 109, Iss. 2, pp. 436-440
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 114-131
Open Access | Times Cited: 138
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial
Sarah Derby, Mark R. Jackson, Karin Williams, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 118, Iss. 5, pp. 1371-1378
Open Access | Times Cited: 11
DNA damage response inhibitors: An avenue for TNBC treatment
Juan Jin, Zhonghua Tao, Jun Cao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1875, Iss. 2, pp. 188521-188521
Closed Access | Times Cited: 52
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Maria Clara Saad Menezes, Farah Raheem, Lida A. Mina, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4332-4332
Open Access | Times Cited: 30
DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Jiayi Li, Ziqi Jia, Dong Lin, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives
Jongmyung Kim, Veronia Fahmy, Bruce G. Haffty
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 5, pp. 211-217
Closed Access | Times Cited: 5
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art
Anna Gueiderikh, Jean Faivre, Constance Golfier, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)
Han Yu, Lei Wei
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-14
Open Access
Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives
Zhenjun Huang, Qing Peng, Luhui Mao, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy
Suryakant Niture, Subhajit Ghosh, Jerry J. Jaboin, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2795-2795
Open Access
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
Amelia Barcellini, Pierre Loap, Kazutoshi Murata, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5380-5380
Open Access | Times Cited: 29
Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
Kassidy M. Jungles, Erin A. Holcomb, Ashley N. Pearson, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Combination of Olaparib with radiotherapy for triple‐negative breast cancers: One‐year toxicity report of the RADIOPARP Phase I trial
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
International Journal of Cancer (2021) Vol. 149, Iss. 10, pp. 1828-1832
Open Access | Times Cited: 26
Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model
Ellen 't Hart, John Bianco, Maaike A. C. Bruin, et al.
Journal of Controlled Release (2023) Vol. 357, pp. 287-298
Open Access | Times Cited: 9
Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer
Rosa Bellavita, Marialuisa Piccolo, Linda Leone, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 6057-6084
Open Access | Times Cited: 3
Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy
May Elbanna, Nayela N. Chowdhury, Ryan Rhome, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 22
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
Armen Parsyan, Jennifer Cruickshank, Kelsey Hodgson, et al.
The Breast (2021) Vol. 58, pp. 6-9
Open Access | Times Cited: 20
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer
Sierra Pellizzari, Harjot Athwal, Anne C. Bonvissuto, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 341-346
Open Access | Times Cited: 2
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
Curtis A. Clark, Eddy S. Yang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
Miki Kawanishi, Mayumi Fujita, Kumiko Karasawa
Breast Cancer Basic and Clinical Research (2022) Vol. 16
Open Access | Times Cited: 10
Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends
Karen Pinilla, Lynsey M. Drewett, Rebecca Lucey, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management
Arnaud Beddok, Paul Cottu, A. Fourquet, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6358-6358
Open Access | Times Cited: 14
Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?
Gabriella Macchia, Francesca Titone, Stefano Restaino, et al.
Healthcare (2023) Vol. 11, Iss. 17, pp. 2413-2413
Open Access | Times Cited: 5
Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date
Sarah Derby, Anthony J. Chalmers, Ross Carruthers
Seminars in Radiation Oncology (2021) Vol. 32, Iss. 1, pp. 15-28
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top